News
-
-
PRESS RELEASE
GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update
GENFIT reports full-year 2024 financial results and corporate update. Net profit of €1.5 million, Iqirvo® commercial launch in PBC, new ACLF datasets, royalty financing. CEO, Pascal Prigent shares progress and outlook -
PRESS RELEASE
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor
Inventiva announces publication in Clinical Gastroenterology and Hepatology of non-invasive biomarker signatures predictive of histological response in MASH patients treated with lanifibranor -
PRESS RELEASE
Inventiva annonce la publication dans Clinical Gastroenterology and Hepatology de l’analyse de nouvelles signatures de biomarqueurs prédictives de la réponse histologique chez les patients atteints de MASH traités par lanifibranor
Inventiva annonce la publication des résultats de l'analyse de nouvelles signatures de biomarqueurs non invasifs prédictives de la réponse histologique chez les patients atteints de MASH traités par lanifibranor -
-
-
-
-
-
